



OPEN ACCESS

EDITED AND REVIEWED BY
Yue Liu,
Xiyuan Hospital, China

*CORRESPONDENCE

Xiaojuan Li,
✉ lixiaojuan@jnu.edu.cn
Jia-Xu Chen,
✉ chenjiayu@hotmail.com

[†]These authors have contributed equally to this work

SPECIALTY SECTION

This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 13 September 2022
ACCEPTED 05 December 2022
PUBLISHED 15 December 2022

CITATION

Zhou X, Liu C, Liu Y, Ma Q, Zhao X, Jiang Y, Li X and Chen J-X (2022),
Corrigendum: Xiaoyaosan alleviates
hippocampal glutamate-induced
toxicity in the CUMS rats via NR2B and
PI3K/Akt signaling pathway.
Front. Pharmacol. 13:1042762.
doi: 10.3389/fphar.2022.1042762

COPYRIGHT

© 2022 Zhou, Liu, Liu, Ma, Zhao, Jiang,
Li and Chen. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Xiaoyaosan alleviates hippocampal glutamate-induced toxicity in the CUMS rats via NR2B and PI3K/Akt signaling pathway

Xueming Zhou^{1,2†}, Chenyue Liu^{1†}, Yueyun Liu¹, Qingyu Ma³,
Xin Zhao¹, Youming Jiang¹, Xiaojuan Li^{3*} and Jia-Xu Chen^{1,3*}

¹School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China,
²School of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Haerbin, China,
³Formula-pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China

KEYWORDS

depression, xiaoyaosan, NR2B, PI3K/Akt pathway, hippocampal CA1 region, glutamate

A Corrigendum on

Xiaoyaosan alleviates hippocampal glutamate-induced toxicity in the CUMS rats via NR2B and PI3K/Akt signaling pathway

by Zhou X-M, Liu C-Y, Liu Y-Y, Ma Q-Y, Zhao X, Jiang Y-M, Li X-J and Chen J-X (2021). *Front. Pharmacol.* 2021, 12: 586788. doi: 10.3389/fphar.2021.586788

In the published article, there was an error in **Figures 5A, 8A** as published. The wrong images were used in **Figure 5A** at the vehicle (W) and vehicle (D) group as well as **Figure 8A**. The correct version of the figure shows below. The corrected **Figures 5, 8** and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.





FIGURE 5

Xiaoyaosan elevates the expression of MAP2 in the hippocampal CA1 region of CUMS rats (A, original magnification, ×200) Xiaoyaosan and Xiaoyaosan + Ly294002 promoted MAP2 expression in the CUMS rats. The green color represents MAP2 staining, and the blue color represents nuclear staining (C) Representative images and western blot analysis (D) of western blot assay showing the relative expression of MAP2 (B) Level of MAP2 mRNA in the hippocampal CA1 area of the rats in the treatment and control groups. All data are expressed as the mean ± SD. [#]*p* < 0.05 compared to the control group; ^{*}*p* < 0.05 compared to the vehicle (W) group; ^Δ*p* < 0.05 compared to the Ly294002 group, *n* = 6.



Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.